“…These publications comprised several methodological problems or bias: (1) some encompassed different epileptic syndromes behind the terms "absence seizures" and "petit mal" and included without clear distinction a mixture of individuals with CAE and other disorders (Lees and Liversedge, 1962;Charlton and Yahr, 1967;Bouma et al, 1996); (2) in other studies, although they have well distinguished different syndromes with absences, the inclusion criteria were either variable from one study to another, or too inaccurate (Bouma et al, 1996;Giannakodimos and Panayiotopoulos, 1996). Another example is the syndrome of "absence epilepsy of early childhood" characterized by an onset before the age of 5 years and that covers a heterogeneous group of epileptic disorders (Doose, 1994); (3) newly described epileptic syndromes such as eyelid myoclonia with absences and perioral myoclonia with absences (Jeavons, 1977;Panayiotopoulos et al, 1995) were not individualized in older studies; (4) the duration of follow-up in many studies was often insufficient after cessation of absence seizures as generalized tonic-clonic seizures or myoclonic jerks may appear later in life (Currier et al, 1963;Gibberd, 1966;Gastaut et al, 1986;Bouma et al, 1996;Wirrell et al, 1996); and (5) therapeutic advances have also probably contributed to this heterogeneity, particularly when old and more recent series were mixed (Bouma et al, 1996). Another example is the syndrome of "absence epilepsy of early childhood" characterized by an onset before the age of 5 years and that covers a heterogeneous group of epileptic disorders (Doose, 1994); (3) newly described epileptic syndromes such as eyelid myoclonia with absences and perioral myoclonia with absences (Jeavons, 1977;Panayiotopoulos et al, 1995) were not individualized in older studies; (4) the duration of follow-up in many studies was often insufficient after cessation of absence seizures as generalized tonic-clonic seizures or myoclonic jerks may appear later in life (Currier et al, 1963;Gibberd, 1966;Gastaut et al, 1986;Bouma et al, 1996;Wirrell et al, 1996); and (5) therapeutic advances have also probably contributed to this heterogeneity, particularly when old and more recent series were mixed (Bouma et al, 1996).…”